Kanvas Biosciences

Spatial biology and synthetic microbiome therapeutics

Company details
Company
Kanvas Biosciences
Stage
Series A

About

Kanvas Biosciences

Kanvas Biosciences is a spatial biology and synthetic microbiome therapeutics company building the world’s first microbiome drug screening, discovery, and manufacturing platform to accelerate the development of next-generation live biotherapeutics. Its proprietary HiPR-FISH technology enables single-cell, strain-level identification of microbes and spatial mapping of their interactions with host immune and epithelial cells. This spatial resolution informs rational design of defined microbial consortia, such as KAN-001 and KAN-004, which target checkpoint inhibitor-refractory cancer and immunotherapy-induced colitis. The company has built a vertically integrated stack including a hyperspectral lightsheet microscope, AI-powered segmentation software, and in-house GMP manufacturing. Kanvas is addressing critical unmet needs in oncology and immune-mediated inflammatory disease through precision-engineered live biotherapeutics.

Our portfolio

Boutique Venture Partners backs authentic founders who transform industries and create new ones in healthcare and life sciences.